An evaluation of emerging vaccines for childhood pneumococcal pneumonia

Julia Webster, Evropi Theodoratou, Harish Nair, Ang Choon Seong, Lina Zgaga, Tanvir Huda, Hope L Johnson, Shabir Madhi, Craig Rubens, Jian Shayne F Zhang, Shams El Arifeen, Ryoko Krause, Troy A Jacobs, Abdullah W Brooks, Harry Campbell, Igor Rudan

Research output: Contribution to journalArticlepeer-review


Pneumonia is the leading cause of child mortality worldwide. Streptococcus pneumoniae (SP) or pneumococcus is estimated to cause 821,000 child deaths each year. It has over 90 serotypes, of which 7 to 13 serotypes are included in current formulations of pneumococcal conjugate vaccines that are efficacious in young children. To further reduce the burden from SP pneumonia, a vaccine is required that could protect children from a greater diversity of serotypes. Two different types of vaccines against pneumococcal pneumonia are currently at varying stages of development: a multivalent pneumococcal conjugate vaccine covering additional SP serotypes; and a conserved common pneumococcal protein antigen (PPA) vaccine offering protection for all serotypes.
Original languageEnglish
Pages (from-to)S26
JournalBMC Public Health
Volume11 Suppl 3
Publication statusPublished - 2011


Dive into the research topics of 'An evaluation of emerging vaccines for childhood pneumococcal pneumonia'. Together they form a unique fingerprint.

Cite this